Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

SHANGHAI JUNSHI BIOSCIENCES CO., LTD.*
上海君實生物醫藥科技股份有限公司

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code: 1877)

VOLUNTARY ANNOUNCEMENT – FDA APPROVAL OF INVESTIGATIONAL NEW DRUG APPLICATION FOR JS212

This announcement is made by Shanghai Junshi Biosciences Co., Ltd.* (上海君實生物醫藥科技股份有限公司) (the "**Company**") on a voluntary basis. Reference is also made to the overseas regulatory announcement of the Company dated 14 December 2025.

The board (the "**Board**") of directors (the "**Directors**") of the Company is pleased to announce that the Company has received a notice from the U.S. Food and Drug Administration (the "**FDA**") that the investigational new drug (the "**IND**") application for EGFR/HER3 bispecific antibody-drug conjugate (code: JS212) for the treatment of advanced solid tumors has been approved by the FDA.

ABOUT JS212

JS212 is a recombinant humanized epidermal growth factor receptor ("**EGFR**") and human epidermal growth factor receptor 3 ("**HER3**") bispecific antibody-drug conjugate ("**ADC**") that is mainly used for the treatment of advanced malignant solid tumor. EGFR and HER3 are highly expressed in a variety of tumor cells, such as lung cancer, colorectal cancer and head and neck cancer etc. There is interaction in signaling pathway between EGFR and HER3, which jointly facilitate the proliferation, survival, migration and angiogenesis of tumor cells. In addition, HER3 is involved in the drug resistance mechanisms of various anti-tumor drugs, including EGFR-targeted drugs and chemotherapy. Comparing to single-target ADC drugs, JS212 can suppress tumors by binding to EGFR or HER3, and is expected to be effective on a wider range of tumors and overcome drug resistance. According to preclinical studies, JS212 has high affinity and specific binding to EGFR and HER3, and exhibits significant antitumor effect in various animal models. JS212 also has a favorable and acceptable safety profile.

The IND application for JS212 was accepted by the National Medical Products Administration (the "**NMPA**") in January 2025 and approved by the NMPA in March 2025. As of the date of this announcement, an open-label, dose-escalation and dose-expansion phase I/II clinical study of JS212 is underway in Chinese Mainland, which is designed to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of JS212 in patients with advanced solid tumors. In addition, the IND application for the multi-cohort combination therapy of JS212 was approved by the NMPA in November 2025, and the relevant clinical studies are planned to commence shortly.

RISK WARNING

Due to the high-tech, high-risk and high-value-added characteristics of pharmaceutical products, there are substantial risks and uncertainties in the process of drug research, development and commercialization. These many stages make it susceptible to uncertainties and therefore, investors are advised to make cautious decisions and pay careful attention to investment risks. The Company will actively pursue the above research and development project and fulfill its information disclosure obligations in a timely manner for subsequent progress of the project in strict compliance with relevant regulations.

By order of the Board
Shanghai Junshi Biosciences Co., Ltd.*
Mr. Xiong Jun
Chairman

Shanghai, the PRC, 14 December 2025

As at the date of this announcement, the Board of Directors of the Company comprises Mr. Xiong Jun, Dr. Li Ning, Dr. Zou Jianjun, Mr. Li Cong, Mr. Zhang Zhuobing, Dr. Yao Sheng, Dr. Wang Gang and Dr. Li Xin as executive Directors; Mr. Tang Yi as a non-executive Director; and Mr. Zhang Chun, Dr. Feng Xiaoyuan, Mr. Li Zhongxian, Ms. Lu Kun and Dr. Yang Jin as independent non-executive Directors.

* *For identification purposes only*